
conferenceseries.com
Accredited
cpd
EVENT
12th Asian Biologics and Biosimilars Congress
August 20-21, 2018 Tokyo, Japan
200+
Participation
15+
Interactive Sessions
10+
Keynote Lectures
50+
Plenary Lectures
3+
Workshops
10+
Exhibitors
B2B
Meetings
http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific

Invitation…

Dear Colleagues,

Conference Series llc LTD extends its welcome to **12th Asian Biologics and Biosimilars Congress** during **August 20-21, 2018** at **Tokyo, Japan** with a theme **"Biologics & Biosimilars: Power of the Past - Force of the Future"**. Conference Series llc LTD through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community.

Conference Series llc LTD Organizes 1000+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board members.

The Asian Biosimilars Congress 2018 brings together biopharmaceutical. industry colleagues, scientists, researchers, regulatory, and clinical experts from around. the globe to bring to you the cutting edge information for the development of biologics and biosimilars and is designed to bring forth the most up to. date information for the development of biosimilars. World-renowned speakers, the. most recent research, advances, and the newest updates in Biologics and Biosimilars are hallmarks of this conference.

Join your peers from around the world for this wonderful opportunity to reach the. largest assembly of participants from the Biologics/Biosimilars community, meet with thought leadership experts, share your new research, and show off your cutting edge technology at this 3-day event.

Organizing Committee Members



Asif Mahmood
Disease Area Cluster Lead for Biosimilars
Pfizer, USA



Devrim Satik
Global Regulatory Affairs AMESA ME Zone Head Sanofi, Turkey



Jianguo Yang
CEO
TAYU Huaxia biotech medical group
Beijing, China



Divya Chadha Manek
Head of Commercial Business
NIHR, United Kingdom



Mahmoud Balbaa
Professor
Alexandria University
Egypt



Michel Mikhail
Senior VP
International Expert in Biosimilars, USA



Pankaj Chaudhari
Manager - Regulatory Affairs (Biosimilars)
IQVIA, India



Pierre A Morgon
CEO MRGN Advisors
Certified CxO
Vaccitech Limited
Switzerland



Tucker Herbert
Sr. Director & Head
MedImmune, USA



Suzette DiMascio
CEO & President
CSI Specialty Group
USA



T. Santha Raju
Sr. Director & Head
MedImmune, USA

Tentative Agenda

August 20, 2018 Monday

Time	Session
08:30-09:30	Registrations
09:30-11:30	Keynote Forum
	Group Photo
11:30-11:45	Network & Refreshments Break*
11:45-13:00	Latest Biosimilars in Asian Scenario | Regulatory Approach for Biosimilars | Brexit Effect on Biosimilars Challenges in Developing Biosimilars
13:00-13:45	Lunch Break**
13:45-16:00	Biosimilar Market and Cost Analysis | Pharmacovigilance of Biosimilars
16:00-16:15	Network & Refreshments Break*
16:15-18:00	Biosimilars Research Pipeline | Globalization of Biosimilars | Biosimilar Companies and Market Analysis

August 21, 2018 Tuesday

Time	Session
08:30-09:30	Registrations
09:30-10:30	Keynote Forum
10:30-11:30	Emerging Trends in Biosimilars | Clinical Studies on Biosimilars
11:30-11:45	Network & Refreshments Break*
11:45-13:00	Emerging Biosimilars in Therapeutics | Biosimilars Analytical Strategies | Bioequivalence Assessment
13:00-13:45	Lunch Break**
13:45-16:00	Legal Issues and BPCI Act | Intellectual Property Rights | BCS & IVIVC Based Biowaivers
16:00-16:15	Network & Refreshments Break*
16:15-18:00	Poster Presentations
	Award Ceremony

Scientific Program

Day 1 August 20, 2018	
Kenote Forum	
10:30-11:30	Title: Biosimilars: A Biologic Revolution - Implications for Safety Asif Mahmood, Pfizer, USA
Networking and Refreshment & Group Photo: 11:30-11:50	
11:50-12:50	Title:Biosimilars Interchangeability: TheDraft regulation in the USA Michel Mikhal, International Expert in Biosimilars, USA
Sessions: Latest Biosimilars in Asian Scenario | Challenges in Developing Biosimilars | Biosimilar Market and Cost Analysis | Clinical Studies on Biosimilars Sessions Chair: TBA	
12:50-13:20	Title: Decoding How Key Stakeholders Drive Biosimilar Adoption Tucker Herbert, Stanford University, USA
Lunch Break: 13:20-14:20	
14:20-14:50	Title: Institutional experiences in clinical evaluation of biosimilars Divya Chadha Manek, NIHR Clinical Research Network, UK
14:50-15:20	Title: Opportunities, Challenges and Strategies for Commercial Success in Global biosimilar Market Pankaj S Chaudhari, Ipca Laboratories, India
Networking and Refreshment & Group Photo: 15:20-15:40	
15:40-16:10	Title: Biosimilars in the United States: A progress report and a peek in to the future Kurt R Karst, Hyman Phelps & McNamara, USA
16:10-16:40	Title: Bioassay-directed isolation of hypotensive alkaloids from Holarrhena pubescens K Aftab, Research Institute of Chemistry, University of Karachi, Pakistan
Panel Discussion	

Day 2 August 21, 2018	
Kenote Forum	
10:00-11:00	Title: Theodor Bilharz Research Institute therapeutic products and health tools Ismaeil Saad, Theodor Bilharz Research Institute, Egypt
11:00-12:00	Title: Expression of shiga-like toxin fused to vascular endothelial growth factor in E.coli for targeting angiogenesis Osama O Ibrahim, Bioinnovation, USA
Lunch Break: 12:00-13:00	
B2B Meeting	
Awards & Closing Ceremony	

This is tentative agenda for the scheduled event. Please note that the timings in this program may subject to change. For more details please contact: biosimilarsasia@conferenceint.com

Conference Highlights

Track 1: Latest Biosimilars in Asian Scenario

Track 2: Regulatory Approach for Biosimilars

Track 3: Challenges in Developing Biosimilars

Track 4: Biosimilar Market and Cost Analysis

Track 5: Pharmacovigilance of Biosimilars

Track 6: Biosimilars Research Pipeline

Track 7: Globalization of Biosimilars

Track 8: Emerging Trends in Biosimilars

Track 9: Clinical Studies on Biosimilars

Track 10: Emerging Biosimilars in Therapeutics

Track 11: Biosimilars Analytical Strategies

Track 12: Legal Issues and BPCI Act

Track 13: Intellectual Property Rights

Track 14: Brexit Effect on Biosimilars

Track 15: BCS & IVIVC Based Biowaivers

Track 16: Biosimilar Companies and Market Analysis

Track 17: Bioequivalence Assessment

Track 18: Entrepreneurs Investment Meet

Past Speakers



Abdel Halim Harrath
King Saud University
Saudi Arabia



Fiona M Greer
SGS Life Sciences
United Kingdom



Alexander Pitters
Kaiser Optical Systems
France



Gregory Glover
Principal at Pharmaceutical Law Group PC
USA



Aparna Kasinath
Syngene International
India



Yahua (Jenny)
Chen, Wolf, Greenfield & Sacks P.C
USA



Alex Brill
American Enterprise Institute
USA



Gordon Bolger
Nucro-Technics Inc., Canada



Angela Furlanetto
DLA Piper (Canada) LLP
Canada



Jianguo Yang
Abpro, USA



Charu Manaktala
Quintiles IMS
India



Krishna Menon
Cellceutix
USA



Andy Upsall
Antibody Analytics
United Kingdom



James Harris
Healthcare Economics LLC
USA



Candida Fratazzi
BBCR Consulting
USA



Kerisha Bowen
Dentons US LLC
USA



Chris Leintz
Pfizer
USA



Marcus Mreyen
Protagen Protein Services, GmbH
Germany



Beat Fluehmann
Vifor Pharma
Switzerland



Kamali Chance
Quintiles, IMS
USA



Christoph Volpers
Michalski & Hüttermann
Germany



Luis Ulloa
Rutgers University-New Jersey Medical School
USA



Dipti Gulati
PJI Biotech
USA



Alan L. Epstein
USC Keck School of Medicine
USA



Christina Vessely
Biologics Consulting, USA



Lisa Mueller
Women In Bio
USA



Denise Kettelberger
Patterson Thuente Pedersen, P.A.,
USA



Afshin Safavi
BioAgilytix Labs
USA



Frank Cheng
Alban Pharma
China



Andreu Soldevila
LeanBioPro
Spain



Darius Panaligan
Merck Biosimilars
Switzerland



Abe Hershkovitz
Hershkovitz & Associates, PLLC
USA



Francesco Marchesi
Regina Elena National Cancer Institute, Italy



András Guttman
University



Gustavo H. Marin
UNLP-CONICET
Argentina



Asif Mahmood
Pfizer
USA



Christelle Dagoneau
Catalent Biologics
USA



Laszlo Endrenyi
University of Toronto
Canada



Timothy Shea
Sterne, Kessler, Goldstein & Fox P.L.L.C.,
USA



Subir Roy
Novartis
India



Ruediger
Jankowsky, Cinfa Biotech GmbH,
Germany



Oxana Iliach
Quintiles IMS
Canada



Daniel Galbraith
BioOutsource Ltd
United Kingdom



Mariana Babayeva
Touro College of Pharmacy
USA



Schellenberger
Volker Schellenberger Amunix Operating Inc., USA



Tom Carver
J A Kemp - Patent and Trade Mark Attorneys
United Kingdom



Samantha (Little) Howard
Covance Clinical Research Unit, Inc.,
United Kingdom



Ricahrd Littlewood
Appliedstrategic
UK



Divya Chadha
Manek, NIHR
UK



Mario DiPaola
Blue Stream Laboratories, Inc,
USA



Mark Emalfarb
Dyadic International, Inc.,
USA



William Sarraille
Sidley Austin LLP
USA



Upendra Nagaich
Amity Institute of Pharmacy
India



Sarfaraz K. Niazi
Adello Biologics LLC
USA



Gene Ransom
CEO MedChi, The Maryland State Medical Society
USA



Patrick Lucy
Pfenex Inc
USA



Nigel Rulewski
Quintiles
USA



Milind Antani
Nishith Desai Associates
India



Wolfgang Rehmann
Taylor Wessing
Germany



Sunit Maity
Zumutor Biologics
India



Hossein
Pakdaman, Iranian Neurological Association
Iran



Robert Salcedo
BioSciences Corp
USA



Raj Dave
Pillsbury Winthrop Shaw Pittman LLP
USA



Noelle Sunstrom
NeuClone Pty Ltd,
Australia



Neil Schauer
Schauer Biologics Consulting, LLC,
USA



Vivek morya
Centre for policy research
India



Jill Myers
Fortress Biotech
USA



Siddhartha Roy
Bose Institute
India



Ronald A Rader
Biotechnology Information Institute
USA



Raymond A Huml
QuintilesIMS
USA



Min Zhang
AstraZeneca
USA



Zhaoyang Li
Sanofi
USA

Glimpses of Asian Biosimilars 2017





















Tourist Attractions

















Venue

Tokyo is Japan's capital and the largest metropolitan area in the world. It is also one of Japan's 47 prefectures, consisting of 23 central city wards and multiple cities, towns and villages west of the city center. The Izu and Ogasawara Islands are also part of Tokyo. Prior to 1868, Tokyo was known as Edo. A small castle town in the 16th century, Edo became Japan's political center in 1603 when Tokugawa Ieyasu established his feudal government there. A few decades later, Edo had grown into one of the world's most populous cities. With the Meiji Restoration of 1868, the emperor and capital moved from Kyoto to Edo, which was renamed Tokyo ("Eastern Capital").

World's highest Skywalk- the Tokyo Sky tree is the tallest free-standing tower in the world, measuring 634m. The observation deck at 450m is the world's highest skywalk and offers panoramic views of the city.

Tokyo is a fascinating city, where the latest trends and the oldest traditions meet. From ancient cherry-blossomfestivals to the vibrant Harajuku neighbourhood, Tokyo offers a seemingly unlimited choice of shopping, entertainment, culture and dining to its visitors.

The city's history can be appreciated in districts such as Asakusa, and in many excellent museums, historic temples and gardens. Contrary to common perception, Tokyo also offers a number of attractive green spaces in the city centre and within relatively short train rides at its outskirts.

You'll fall in love with Japan



Venue:

Radisson Narita, Tokyo
650-35 Nanae, Tomisato-Shi
Narita 286-0221, Japan

Mail us to know more!

For Abstract Submission Guidelines | For Reserving your slot | Proposals | Registration | Posters | Accommodations
No doubt you have lots of queries...
Why not get in touch..!
Drop us your query with details and we will call you right away

For Queries
Contact: Victorya Jones | Program Director
Email: asianbiosimilars@pharmaceuticalconferences.com
Office Ph: +1-650-889-4686 Ext: 6093

For Exhibition & Sponsorship
Contact: Victorya Jones
Email: asianbiosimilars@pharmaceuticalconferences.com

Hosted by Conference Series llc LTD
47 Churchfield Road, London, W3 6AY
Toll Free: +1800-216-6499
asianbiosimilars@pharmaceuticalconferences.com